Akzo Nobel Staff Sick Fund Approved

19 October 1997

The Dutch Sick Fund Council has approved the setting-up of a specialsick fund by Akzo Nobel, opening the way for more such funds. The plan, which will cover about 20,000 people and be named the Independent Sick Fund Enterprise (OZB), now goes to the government for approval.

Akzo decided to set up the fund for its staff, who are compulsorily insured and covered by the national health system, when its existing top-up scheme came under pressure from moves to make insurance more competitive. The Council said the plan meets its requirements in that it has no profit motive, has at least 1.1 million guilders ($557,810) in cash and is open to all. The employers organization VNO-NCM welcomed the initiative, saying that it will keep insurers "on their toes," and hope that others will follow.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight